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Abstract
Purpose—Glaucoma medications can reduce intraocular pressure and improve clinical outcomes 
when patients adhere to their medication regimen. Providers often ask glaucoma patients to self-
report their adherence, but the accuracy of this self-report method has received little scientific 
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attention. Our purpose was to compare a self-report medication adherence measure with adherence 
data collected from Medication Event Monitoring Systems (MEMS) electronic monitors. 
Additionally, we sought to identify which patient characteristics were associated with over-
reporting adherence on the self-reported measure.
Methods—English-speaking adult glaucoma patients were recruited for this observational cohort 
study from six ophthalmology practices. Patients were interviewed immediately after a baseline 
medical visit and were given MEMS containers, which were used to record adherence over a 60-
day period. MEMS data were used to calculate percent adherence, which measured the percentage 
of the prescribed number of doses taken, and timing adherence, which assessed the percent doses 
taken on time. Patients self-reported adherence to their glaucoma medications on a visual analog 
scale (VAS) approximately 60 days following the baseline visit. Bivariate analyses and logistic 
regressions were used to analyze the data. Self-reported medication adherence on the VAS was 
plotted against MEMS adherence to illustrate the level of discrepancy between self-reported and 
electronically-monitored adherence.
Findings—The analyses included 240 patients who returned their MEMS containers and who 
self-reported medication adherence at the 60-day follow-up visit. When compared with MEMS-
measured percent adherence, 31% of patients (n=75) over-estimated their adherence on the VAS. 
When compared with MEMS-measured timing adherence, 74% (n=177) of patients over-estimated 
their adherence on the VAS. For the MEMS-measured percent adherence, logistic regression 
revealed that patients who were newly prescribed glaucoma medications were significantly more 
likely to over-report adherence on the VAS (OR=3.07, 95% CI: 1.22, 7.75). For the MEMS–
measured timing adherence, being male (chi-square=6.78, p=0.009) and being prescribed 
glaucoma medications dosed multiple times daily (chi-square =4.02, p=0.045) were significantly 
associated with patients over-reporting adherence on the VAS. However, only male gender 
remained a significant predictor of over-reporting adherence in the logistic regression, (OR=4.05, 
95% CI: 1.73, 9.47).
Implications—Many glaucoma patients, especially new patients, over-estimated their 
medication adherence. Because patients were likely to over-report percent doses taken and timing 
adherence, providers may want to ask patients additional questions about when they take their 
glaucoma medications in order to potentially detect issues with taking glaucoma medications on 
time.
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INTRODUCTION
Glaucoma is a leading cause of irreversible blindness worldwide affecting over 60 million 
people.1,2 As the global population ages, it is projected that glaucoma will affect 
approximately 110 million by 2040.2 Glaucoma is often detected late, usually after patients 
have already experienced extensive and irreversible damage3. Subsequent glaucoma 
management is vital to preserve vision.3,4 Topical medications, which lower intraocular 
pressure (IOP), are used to delay the progression of glaucoma; however, patients may not 
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notice the benefits of using these medications because glaucoma is an asymptomatic, slowly 
progressive chronic disease.5–7 Additionally, approximately one-half of those who start 
therapy on IOP-lowering medications discontinue them within six months.8,9 Patients who 
are nonadherent to their IOP-lowering medications risk being prescribed additional 
glaucoma medications or hastening the progression of glaucoma. Therefore, regular and 
accurate assessment of medication adherence in clinical practice is essential.
Pharmacy refill methods10–12, electronic monitoring13–19, and self-report measures15,18,20 
have all been used to assess the medication adherence of glaucoma patients. Estimates of 
adherence vary based on the method being used; pharmacy refill records have produced the 
lowest estimates of glaucoma medication adherence while self-report measures have yielded 
the highest adherence estimates.15 Refill records are limited in that they may contain 
missing information21, are restricted in the types of adherence that can be assessed (e.g., 
interdose intervals cannot be calculated), and may be too cumbersome for providers to 
incorporate into practice. Although electronic monitors have been referred to as the “gold 
standard” for adherence measurement22–24, their cost makes them impractical for 
monitoring adherence in clinical settings. Furthermore, certain electronic monitors can only 
be used with specific medications (e.g., Travatan Dosing Aid).16,17,25,26 Neither pharmacy 
refill records nor electronic monitoring can verify whether the patient actually instilled their 
eye drops.
Self-reported adherence measures may be the most cost-effective and feasible way for 
providers to assess the adherence of glaucoma patients, although their validity is often called 
into question. A few studies have examined the validity of self-reported measures against 
objective measures (e.g., pharmacy records or electronic monitors) in glaucoma 
patients.15,18 Both studies found that patients with glaucoma tended to over-estimate their 
adherence to glaucoma medications.15,18 Furthermore, Cook et al15 found that the 
correlation between MEMS and self-report was only 0.31. These previous examinations of 
self-report versus objective measures have been limited in several respects. The Cate et al 
study18 was limited to a single study site, a single medication (travoprost), and only had 88 
participants. Cook15 examined a single type of MEMS-measured adherence (percentage of 
days with correct adherence) and was also restricted to patients taking a single glaucoma 
medication.
The objectives of this multi-site study were (1) to compare patients’ self-reported adherence 
to glaucoma medications via the use of a visual analog scale as compared with MEMS-
measured percent adherence and MEMS-measured timing adherence, and (2) to examine the 
patient characteristics of those who over-reported their adherence on the visual analog scale. 
The current study builds upon previous studies by examining discrepancies in self-reported 
adherence by using two measures of electronically-monitored adherence for a sample 
(n=240) that included glaucoma patients who were taking multiple medications. The study is 
also the first to examine which patient characteristics are associated with glaucoma patients 
over-reporting adherence.
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From December 2009 through July 2012, English-speaking adults with primary open-angle 
glaucoma were recruited at six ophthalmology clinics located in four states (Georgia, North 
Carolina, Maryland, Utah), and were followed for approximately 8 months. At each clinic, 
providers (e.g., ophthalmologists) gave their written consent. Clinic staff referred potentially 
eligible patients to a clinic-based research assistant. The research assistant explained the 
study to the patients and obtained informed consent from the patient before the patient’s 
baseline medical visit. Eligibility requirements included being at least 18 years of age, being 
able to speak and read English, being considered either a glaucoma or a glaucoma suspect 
patient, being mentally competent as determined by the Mental Status Questionnaire27, and 
being prescribed at least one glaucoma medication. After the medical visit, the research 
assistant interviewed the patient using a survey. Ineligible patients were thanked and given 
$5. The research assistant furnished the patient with one MEMS container for each 
prescribed glaucoma medication, and demonstrated how to place the glaucoma medication 
inside the MEMS container and how to use the MEMS container. This “bottle within a 
bottle” system has been used previously to measure glaucoma patient medication 
adherence.14,15,17
Approximately 60 days after their baseline medical visit, the patients returned to the clinic 
for a follow-up visit. At that time, the research assistant interviewed the patient using a 
survey that included the visual analog scale (VAS) and downloaded the data from each 
MEMS container. Eligible patients enrolled in the study were given $20 at the initial and the 
follow-up visit.
This study was approved by the Institutional Review Boards at the University of North 
Carolina, Duke University, Emory University, and the University of Utah.
Patient Characteristics
The research assistant gathered data regarding patient age, race, gender, years of education, 
household income, and whether the patient was newly prescribed a glaucoma medication 
from the patient during the patient interview after the patient’s medical visit. Self-reported 
patient race was measured as a categorical variable (White, African American, Asian, Native 
American, and Hispanic), and then recoded into African American and non-African 
American. Annual household income was measured as a categorical variable, and then 
recoded into a dichotomous variable (< $20,000 versus ≥ $20,000); $20,000 is the 
approximate federal poverty level for a family of three.28 Whether the patient was newly 
prescribed glaucoma medications was measured as a dichotomous variable (new to 
medication or already using medication).
Information about the patient’s glaucoma severity was extracted from the patient’s medical 
record. Specifically, the research assistant recorded the patient’s mean deviation, in decibels 
(dB), from the patient’s most recent reliable visual field test for each eye. We classified the 
severity of glaucoma using the mean deviation of the worse eye, and recoded it as mild (≥ 
−6 dB), moderate (between −12 dB and −6 dB), or severe (≤ −12 dB).29
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The research assistant extracted the number of prescribed glaucoma medications and the 
corresponding dosing regimen from the patient’s medical record. The number of glaucoma 
medications was measured as a continuous variable, and then recoded into a dichotomous 
variable (one versus more than one). The medication dosing regimen was measured as a 
dichotomous variable (once daily versus more than once daily).
Self efficacy
During the initial interview, patients completed a 10-item, validated, glaucoma medication 
self-efficacy questionnaire.19,30 This glaucoma medication adherence self-efficacy 
questionnaire assesses patients’ confidence in medication adherence and has been strongly 
correlated with medication adherence as measured with electronic monitoring.30 Responses 
for each item are “not at all confident” (coded as 1), “somewhat confident” (coded as 2), and 
“very confident” (coded as 3). Items were summed, with scores ranging from 10 to 30. 
Higher scores indicating greater glaucoma medication self-efficacy. The internal consistency 
of the self-efficacy questionnaire in this study was α =0.94.
Medication Adherence
The visual analog scale (VAS), a self-report measure of adherence, has been validated 
against prescription medication refills for chronic disease patients.31–34 As part of the 
follow-up visit interview, the research assistant asked the patient “All things considered, 
how much of the time do you use ALL of your glaucoma medications EXACTLY as 
directed?” and instructed the patient to place a mark through the 100 mm line to indicate 
their answer (range is 0 mm = None of the time, 100 mm = All of the time).31–35 This 
question can be seen in Figure 1. Using a metric ruler, placing the 0 mm portion of the ruler 
on the left-most portion of the VAS line, the data entry person measured the placement of 
the patient-placed mark in millimeters. In order to facilitate comparisons between the VAS 
and MEMS, we converted the measurement on the VAS from 100 mm to 100%.35
Electronic monitoring of medication adherence was assessed over a 60-day period via 
MEMS (AARDEX, MeadWestvaco Corporation, Richmond, VA, USA). We chose to 
measure the first 60 days because the most of the follow-up visits occurred between 4 and 
12 weeks after the initial visit. This electronic monitor records the date and time of each 
bottle opening. The model that was used in this study did not have a LCD display on the 
cap. If a patient was assigned more than one MEMS container, then color-coded labels were 
placed on the outside of the MEMS bottle so that the patient knew which MEMS bottle 
contained which glaucoma medication.
We used the data from the MEMS device to examine the percent doses prescribed that were 
taken during the 60-day period (MEMS-measured percent adherence). For example, if a 
patient were prescribed a twice daily medication, then the bottle should have been opened 
120 times over a 60-day period. If the patient only opened the bottle 80 times, then their 
percent adherence would be 80 divided by 120, or 75%. We capped the maximum MEMS-
measured percent adherence at 100% since the VAS score could not be greater than 100. If 
the patient was prescribed more than one glaucoma medication, the average of the percent 
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doses prescribed was used since the wording on the VAS question referred to how the 
patient takes all glaucoma medications instead of a referring to a specific medication.
Additionally, the MEMS-measured timing adherence assessed the percent doses taken on 
time during the 60-day period. We used the default MEMS measure of on-time – such that if 
a patient was prescribed a once daily dosing regimen, then taking the medication on time 
was considered every 24 hours ± 6 hours. If the dosing regimen was twice daily, then taking 
the medication on time meant taking it every 12 hours ± 3 hours. If the patient was 
prescribed more than one glaucoma medication, the average of the on-time adherence 
percentage was used.
Data Analyses
All analyses were performed using IBM SPSS Statistics version 21 (Armonk, NY, USA). 
We set the a priori level of statistical significance at p < 0.05. First, we used descriptive 
statistics to characterize the patient demographics. Then, we used t-tests and chi-square tests 
to determine which patient characteristics (age, gender, race, years of formal education, 
household income, was newly prescribed glaucoma medications, glaucoma severity, number 
of prescribed glaucoma medications, glaucoma medication dosing frequency, and glaucoma 
medication self-efficacy) were associated with over-reporting adherence on the VAS versus 
MEMS. Also, logistic regression analyses were conducted to determine which patient 
characteristics predicted whether the patient over-reported adherence on the VAS as 
compared with that calculated via MEMS. If the VAS medication adherence was greater 
than the MEMS-measured percent adherence, then the patient over-reported adherence on 
the corresponding scale; otherwise, the patient did not over-report adherence. Lastly, we 




Eighty-six percent (n=279) of eligible patients participated in this study. Thirty patients 
(11%) patients did not have either MEMS-measured adherence values because they either 
did not return a bottle or returned a bottle where the data could not be downloaded (e.g. 
hardware failure). Patient characteristics are presented in Table I.
Of the 279 patients who participated in the study, 240 had both a VAS score and a 60-day 
MEMS-measured adherence value for each of their prescribed glaucoma medication. The 
median self-reported adherence percentage on the VAS was 95.0% (interquartile range: 84.0 
– 98.0). The median MEMS-measured percent adherence was 97.5% (interquartile range: 
88.1 – 100.0) and the median MEMS-measured timing adherence was 83.7% (interquartile 
range: 58.4 – 94.9). Included in this data is one patient who did not use any of the prescribed 
glaucoma medications during the study period. The median MEMS-measured percent 
adherence did significantly differ from the median self-reported adherence (z=−3.33, 
p=0.001). The median MEMS-measured timing adherence did significantly differ from the 
median self-reported adherence (z=−8.78, p<0.0001).
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The sensitivity of the VAS adherence being at least 80% was 0.85, but the specificity was 
0.38 when compared with the MEM-measured percent adherence. Also, when compared 
with the MEMS-measured timing adherence, the sensitivity of the VAS adherence being at 
least 80% was 0.92, but the specificity was 0.32.
Thirty-one percent (n=75) of patients over-estimated their adherence on the VAS when 
compared with the MEMS-measured percent adherence and 58% (n=140) under-estimated 
their adherence. The self-reported adherence on the VAS had a modest relationship with the 
MEMS-measured percent adherence (r=0.32, p<0.001). Figure 2 illustrates the scatter plot 
displaying MEMS-measured percent adherence against self-reported medication adherence 
on the VAS.
Seventy-four percent (n=177) of patients over-estimated their adherence on the VAS when 
compared with the 60-day MEMS-measured timing adherence value and 25% (n=59) of 
patients under-estimated their adherence. There was a modest relationship between the VAS 
score and the MEMS-measured timing adherence (r=0.38, p<0.001). Figure 3 presents the 
scatter plot showing MEMS-measured timing adherence against self-reported medication 
adherence on the VAS.
Table II presents the characteristics of the glaucoma patients who over-reported adherence 
to their medication regimens on the VAS when compared with the MEMS-measured percent 
adherence. Patients who were newly prescribed medications at the baseline visit were 
significantly more likely to over-report their adherence on the VAS as compared with 
patients who were already using medications at the baseline visit (chi-square=15.2, 
p<0.001). Logistic regression revealed that patients who were newly prescribed glaucoma 
medications were significantly more likely to over-report adherence on the VAS as 
compared with those already using medications at the baseline visit (OR=3.07, 95% CI: 
1.22, 7.75, p=0.018).
Table III presents the characteristics of the patients who over-reported adherence to their 
medication regimens on the VAS when compared with the MEMS-measured timing 
adherence. Males (chi-square=6.78, p=0.009) and patients prescribed glaucoma medications 
more than once daily (chi-square=4.02, p=0.045) were significantly more likely to over-
estimate their adherence. Logistic regression revealed that only males (OR=4.05, 95% CI: 
1.73, 9.47, p=0.001) were significantly more likely to over-report adherence on the VAS 
when compared with MEMS-measured timing adherence.
DISCUSSION
This is the first study to examine whether there are discrepancies between self-reported 
adherence and two measures of electronically-monitored adherence (percent adherence, 
timing adherence) in a sample of glaucoma patients that included patients who were taking 
multiple medications. We found that patients’ self-reported medication adherence as 
measured with a visual analog scale did not correlate strongly with electronically-measured 
percentage or timing adherence over a 60-day period. Patients were more likely to over-
report timing adherence than percentage adherence, and patients who were new to 
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medications and men were more likely to over-report adherence. This study focused on the 
over-reporting of medication adherence rather than under-reporting since the consequences 
of over-reporting may lead to optic nerve degeneration which could ultimately lead to 
blindness.
When compared with the MEMS-measured percent adherence, nearly one in three patients 
over-estimated their adherence on the VAS, which is lower than what prior studies36,37 have 
found in other chronic disease states. However, this was higher than a previous study of 
glaucoma patients, which found a discrepancy of approximately 15% between MEMS-
measured percent adherence and a self-report adherence measure.15 The level of discrepancy 
we found was more similar to a previous study of 88 glaucoma patients where electronically 
measured adherence detected approximately 25% more non-adherent patients when 
compared with selfreport.18 When compared against the MEMS-measured timing 
adherence, approximately three out of four patients over-reported their adherence on the 
VAS, which is similar to what studies have found in other chronic diseases.36,37 Taken 
together, these findings suggest that patients using medications chronically tend to over-
estimate adherence to their prescribed dosing schedule.
When compared with the MEMS-measured percent adherence, patients who were newly 
prescribed medications at the baseline visit were significantly more likely to over-report 
their adherence on the VAS as compared with those who were already using glaucoma 
medications at the baseline visit. Previous research18 did not find any significant differences 
in electronically-measured adherence rates between those glaucoma and ocular hypertension 
patients who were new versus established on drops; however, that study had a much smaller 
patient sample. Patients who are new to drops may have more difficulty integrating a new 
medication into their daily routine. Additionally, many new glaucoma patients discontinue 
their medications within the first six months of treatment8,9. Taken together, providers 
should attempt to accurately assess the medication adherence of new patients at the first 
follow-up visit following the initiation of glaucoma pharmacotherapy. Because patients were 
likely to over-report percent doses taken and timing adherence, providers may want to ask 
patients additional questions about when they take their glaucoma medications in order to 
potentially detect issues with taking glaucoma medications on time, by starting a 
conversation such as, “some patients have a hard time remembering to take their glaucoma 
medications on a consistent schedule, tell me how you remember to take your medications 
on time”.
Males over-reported their adherence on the VAS as compared to the MEMS-measured 
timing adherence, which is similar to a study26 involving glaucoma patients self-reporting 
adherence. Additionally, patients who were prescribed glaucoma medications dosed multiple 
times per day were significantly more likely to over-report adherence on the VAS, which is 
similar to what other studies have found.15,26,37 This may be due to complex dosing 
regimens that may interfere with the patient’s normal activities and is a good reason for 
providers to simplify medication regimens whenever possible. If a glaucoma medication is 
to be taken multiple times daily, the provider should help the patient develop a plan (e.g., 
take before breakfast and after dinner) to incorporate this into the patient’s daily life. Other 
patient characteristics, such as years of education, household income, and age, were not 
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significantly associated with over-reporting medication adherence on the VAS, contrasting 
the results of other studies, which may be due, in part, to the differences in the patient 
populations amongst the studies.15,38
There may be several reasons why patients over-estimate their adherence. First, information 
on the purpose of using glaucoma eye drops, the importance of adhering to the prescribed 
regimen, or the frequency with which to administer drops might be inadequately 
communicated to or misunderstood by the patient.39 As a result, the patient may self-
administer their medications less frequently than prescribed while genuinely believing that 
they are taking their medications as their provider prescribed. Furthermore, some patients 
may have felt the need to please the research assistant during the interview by stating better 
adherence than actuality (i.e. social desirability bias). Also, some patients may not have 
remembered missing doses when self-reporting adherence. Even so, when comparing the 
average VAS self-reported adherence with the average MEMS electronically-monitored 
adherence, it was surprising that this was relatively close when comparing 60-day adherence 
using electronic monitor with a patient-reported adherence measure. In a small study of 
patients who had been taking at least one antihypertensive medication on a stable medication 
regimen for at least 3 months, it was found that the VAS medication adherence at 30 days 
was more closely related to adherence measured by electronic monitors than the VAS 
medication adherence at either 7 or 14 days.41 However, that study did not evaluate the self-
reported medication adherence on the VAS with that measured with electronic monitors for 
longer than 30 days.
The wording of the VAS questions may have influenced how the patients self-reported 
adherence in this study. The wording of the question was “All things considered, how much 
of the time do you use ALL of your glaucoma medications EXACTLY as directed?” with 
instructions for the patient to place a mark anywhere on the 100 mm line for the patient to 
indicate their adherence. Even if the written instructions were not clearly understood by the 
patients, research assistants could clarify the question and answer any questions that the 
patient had with this particular question. We did not place visual cues on the VAS line to 
provide general percentage guidance (i.e., every 10%). Furthermore, the instructions did not 
provide a specific time period for recall, so patients may have been recalling their adherence 
over the past few days or weeks rather than the past 60 days. Fewer people over-estimated 
their adherence on the VAS when compared to the MEMS-measured percent adherence and 
MEMS-measured timing adherence values (31% and 74% respectively). Because the time at 
which patients take their medications may not be information that is readily accessible 
cognitively, patients may need additional questions that ask specifically what time of day 
they take their medications and whether they believe they are taking their medications on 
time each day in order to accurately recall this information. This might also explain why the 
VAS had moderate sensitivity and had poor specificity for detecting when a glaucoma 
patient was at least 80% adherent to their glaucoma medication regimen. Indeed, future 
research is needed to identify what changes are needed to the VAS to make it more useable 
in the glaucoma patient population. Additionally, future research should evaluate whether 
there is a difference in patient adherence across medication classes (e.g., prostaglandin 
analogs, beta blockers, carbonic anhydrase inhibitors, alpha agonists, combination products).
Sayner et al. Page 9













An unexpected result from this study is that the glaucoma medication self-efficacy was not 
correlated with either MEMS adherence measure. This may be due to the differences in the 
patient populations between this study and one validating this questionnaire19. This current 
study had fewer males, more patients who were newly prescribed glaucoma medications, 
and more patients prescribed a single glaucoma medication than the study which validated 
the self-efficacy questionnaire.
There were limitations in our study, and as such, results should be interpreted with caution. 
First, the patient self-reported adherence to a research assistant and may have given a 
different estimate of adherence than they would to a provider. Another limitation was that 
patients were told that the MEMS bottle would be used to monitor their medication-taking 
behavior, which may have influenced their adherence as well as their estimations of 
adherence. To minimize this potential adherence-enhancing effect of using the electronic 
monitors, we evaluated adherence over 60 days. Also, the MEMS bottle only measured 
whether the patient opened the bottle instead of whether the patient took the dose or instilled 
the eye drop correctly. As such, patients may have taken into account additional factors 
when placing the mark on the VAS indicating their adherence to glaucoma medications 
which may account of the large number of patients who under-reported their adherence. 
Additionally, selection bias could be another limitation since the ancillary staff did not track 
the characteristics of the patients who declined to speak with the research assistant to learn 
more about the study. Also, patients self-reported whether they were newly prescribed a 
glaucoma medication or were already using a glaucoma medication at the initial visit. 
However, even with these limitations, this study has found several patient characteristics 
that were associated with glaucoma patients who over-report adherence.
CONCLUSION
In summary, this study found that many glaucoma patients over-reported their glaucoma 
medication adherence on the VAS as compared with electronic monitors. Providers should 
be aware of this as a possible reason for a patient’s non-response to treatment. Because more 
objective methods of determining adherence, such as pharmacy refill records or electronic 
monitors, may be too time-consuming or expensive for providers to incorporate into their 
practices, providers may need to use non-threatening patient interview techniques40 to elicit 
reports of non-adherence during medical visits until more valid and reliable self-report 
measures can be developed and tested. Future studies should evaluate whether wording or 
visual modifications on self-reported adherence measures could elicit more accurate and 
reliable reports of medication adherence from glaucoma patients.
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The question containing the visual analog scale (VAS) on the survey
Sayner et al. Page 14














Relationship between the 60-day MEMS-measured adherence and patients’ self-reported 
adherence assessed by visual analog scale (VAS) at the follow-up visit (N = 240)
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Relationship between the 60-day MEMS-measured timing adherence and patients’ self-
reported adherence assessed by visual analog scale (VAS) at the follow-up visit (N = 240)
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Table I
Patient characteristics (N = 279)
Characteristic % (N)
Gender, Male 40.9 (114)
Race, African American 35.5 (99)
Patient newly prescribed glaucoma medication at baseline 18.3 (51)
Glaucoma severity in worse eye, Severe 15.1 (42)
Number of glaucoma medications
  One 67.4 (188)
  Two 28.3 (79)
  Three 3.9 (11)
  Four 0.4 (1)
Daily dosage of glaucoma medication
  Once daily 59.5 (166)
  More than once daily 36.9 (103)
Household income
  Less than $20,000 10.8 (30)
  $20,000 or more 65.6 (183)
  Do not know / Do not want to answer 23.3 (65)
Mean (Standard Deviation); Range
Age 65.8 (12.8)
21 – 93
Years of schooling 15.1 (3.5)
5 – 26
Self-efficacy glaucoma medications 27.8 (3.1)
13 – 30
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Table II
Patient characteristics1 of those who over-reported adherence to glaucoma medications on the VAS as 
compared with MEMS-measured adherence
Over-reported adherence
on the VAS
(N = 75) P
Gender, Male 33 / 75 (44%) 0.501
Race, African American 28 / 75 (37%) 0.505
Patient newly prescribed glaucoma medication at baseline 25 / 75 (33%) < 0.001
Glaucoma severity in worse eye, Severe 15 / 71 (21%) 0.278
Prescribed more than 1 glaucoma medications 19 / 75 (25%) 0.052
Glaucoma medication dosed more often than once daily 24 / 72 (33%) 0.905
Household income, <$20,000 annually 6 / 57 (11%) 0.474
Mean (Standard Deviation)
Age 65.3 (12.7) 0.494
Years of schooling 15.2 (3.8) 0.351
Self-efficacy glaucoma medications, short form 27.6 (3.4) 0.808
1
Patient characteristics as defined in the Methods section (e.g., male patients compared with female patients, African American patients compared 
with non-African American patients)
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Table III
Patient characteristics1 of those who over-reported adherence to glaucoma medications on the VAS as 
compared with MEMS-measured timing adherence
Over-reported adherence
on the VAS
(N = 177) P
Gender, Male 81 / 177 (46%) 0.009
Race, African American 63 / 177 (36%) 0.547
Patient newly prescribed glaucoma medication at baseline 35 / 177 (20%) 0.321
Glaucoma severity in worse eye, Severe 33 / 166 (20%) 0.214
Prescribed more than 1 glaucoma medications 63 / 177 (36%) 0.497
Glaucoma medication dosed more often than once daily 77 / 170 (45%) 0.045
Household income, <$20,000 annually 18 / 135 (13%) 0.973
Mean (Standard Deviation)
Age 65.4 (12.8) 0.605
Years of schooling 14.9 (3.6) 0.508
Self-efficacy glaucoma medications, short form 27.8 (3.2) 0.736
1
Patient characteristics as defined in the Methods section (e.g., male patients compared with female patients, African American patients compared 
with non-African American patients)
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